Recombinant LAG3 (Relatlimab Biosimilar) 抗体
This 小鼠 单克隆 anti-LAG3 (Relatlimab Biosimilar) antibody specifically detects LAG3 (Relatlimab Biosimilar) in FACS 和 in vivo. The antibody is reactive with 人 samples.
产品编号 ABIN7795123
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant LAG3 (Relatlimab Biosimilar) 抗体 (ABIN7795123)
抗原
LAG3 (Relatlimab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
小鼠
克隆类型
单克隆
标记
This LAG3 (Relatlimab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody
-
产品特性
- What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human LAG-3
-
-
anti-LAG3 (Relatlimab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Human Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- LAG3 (Relatlimab Biosimilar)
-
别名
- Relatlimab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
